Piclidenoson is an A3AR highly specific agonist, inducing a robust anti-inflammatory effect demonstrated in preclinical pharmacology studies in rheumatoid arthritis, osteoarthritis, uveitis, and colitis [14–19]. Here, ADORA3 is linked to rheumatoid arthritis.